Literature DB >> 25841463

Checkpoint inhibitors in treatment of metastatic mucosal melanoma.

Bin Lian1, Jun Guo2.   

Abstract

Mucosal melanoma (MM) is rare and of extremely poor prognosis. Although significant progress has been made in developing new therapies for patients with metastatic melanoma arising from the cutaneous, knowledge about the effects of treatments for patients with MM is limited. In this review we aim to summarize and evaluate related trials.

Entities:  

Keywords:  Anti-programmed cell death 1; checkpoint; immunotherapy; ipilimumab; mucosal melanoma (MM)

Year:  2014        PMID： 25841463     DOI： 10.3978/j.issn.2304-3865.2014.07.05

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN： 2304-3865


  3 in total

1.  [Localized, irregular pigmentation of the maxillary gingiva].

Authors:  R K Rahimi-Nedjat; K Sagheb; A Tuettenberg; C Renné; C Walter
Journal:  Hautarzt       Date:  2016-04       Impact factor: 0.751

Review 2.  Primary malignant mucosal melanoma of the upper lip: a case report and review of the literature.

Authors:  Narayan Sharma Lamichhane; Jiping An; Qilin Liu; Wei Zhang
Journal:  BMC Res Notes       Date:  2015-09-29

3.  Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.

Authors:  Claire Mignard; Aurélie Deschamps Huvier; André Gillibert; Anne Bénédicte Duval Modeste; Caroline Dutriaux; Amir Khammari; Marie-Françoise Avril; Nora Kramkimel; Laurent Mortier; Pierre Marcant; Thierry Lesimple; Caroline Gaudy-Marqueste; Candice Lesage; Laurent Machet; François Aubin; Nicolas Meyer; Nathalie Beneton; Géraldine Jeudy; Henri Montaudié; Jean-Philippe Arnault; Laetitia Visseaux; Sabiha Trabelsi; Mona Amini-Adle; Eve Maubec; Yannick Le Corre; Dan Lipsker; Ewa Wierzbicka-Hainaut; Noémie Litrowski; Andreea Stefan; Florence Brunet-Possenti; Marie-Thérèse Leccia; Pascal Joly
Journal:  J Oncol       Date:  2018-12-02       Impact factor: 4.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.